Interventions to improve cardiopulmonary resuscitation: a review of meta-analyses and future agenda

Athanasis Chalkias1,2 and John P. A. Ioannidis3,4,5,6,7*

Hardly any other medical intervention is as directly relevant for life-and-death outcomes as cardiopulmonary resuscitation (CPR). One would have expected, therefore, extensive evidence from rigorous randomized controlled trials (RCTs) for fine-tuning best approaches that maximize CPR effectiveness. However, this is not the case. Professional guidelines reflect little tangible progress, and recommendations are not driven by strong effects seen in RCTs.

To map the landscape of meta-analyses of RCTs on CPR, we searched PubMed (April 8, 2019) for “cardiopulmonary resuscitation AND meta-analysis AND (randomized OR randomised).” We screened 114 retrieved items for meta-analyses of RCTs in real patients (not education or simulation/manikins), addressing aspects pertaining to CPR per se rather than interventions done afterwards (e.g., hypothermia) and using survival and/or neurologically intact survival as outcomes. Whenever multiple overlapping meta-analyses existed, we kept all of them if they were published after 2013, to examine consistency of results.

The available evidence (Table 1) suggests that we have a dearth of interventions that improve survival rates at hospital discharge and, even less so, neurological outcomes [1–12]. All benefits, if any, pertain to out-of-hospital cardiac arrest circumstances, while no new technology or improvement seems to work for in-hospital arrests. For out-of-hospital cardiac arrests, continuous (versus interrupted) chest compressions, epinephrine, and use of endotracheal tube intubation (versus supraglottic airway devices) may achieve modest increases in survival at hospital discharge. However, the 95% confidence intervals of the risk ratios in the most recent, inclusive meta-analyses on these interventions reach down to 1.00–1.02. Therefore, we cannot exclude that even these benefits are negligible or even non-existent. Survival with neurologically intact outcome is not conclusively increased by any of the interventions listed in the Table 1; epinephrine achieves a nominally statistically significant modest benefit over pooled control treatments, but this is less clear in separate comparisons against different control options. Epinephrine saves some patients who are admitted to the hospital, but they are not discharged neurologically intact. Other interventions also have disappointing results, e.g., no clear benefit is seen with mechanical devices for chest compression (they are even harmful for in-hospital cardiac arrest) and the order of chest compression versus defibrillation may not matter.

This rather disheartening evidence pertains largely to short-time follow-up. Longer-term outcomes are essential to make informed choices, but these data are rarely available from RCTs. One can try to supplement the evidence gap with observational datasets, and this is becoming increasingly convenient as large datasets become routinely available. However, for what are likely to be modest or subtle differences, it is unlikely that observational data will be sufficiently error-free to be conclusive. Many observational studies in this field claim sizeable survival differences, but their credibility is questionable—they need to be validated in carefully done RCTs [13]. For example, a highly cited observational study has found that endotracheal intubation is harmful for in-hospital arrest [14]. The availability of data on over 100,000 patients results in a very tight 95% confidence interval for neurological outcome and an astronomically low \( p \) value. However, this precision is misleading because potential bias may completely invalidate this conclusion.

In contrast to massive observational datasets, the RCTs done to-date and even their meta-analyses have usually had rather limited sample sizes. Clinically meaningful differences between the tested interventions may
### Table 1 Meta-analyses of randomized controlled trials with survival and neurologically intact survival as outcomes

| Comparison (setting) | N randomized | Outcome measures (timing) | Relative risk (95% CI) | Heterogeneity |
|----------------------|-------------|---------------------------|------------------------|--------------|
| **Chest compressions** |             |                           |                        |              |
| Meier et al. [1]     | 1503        | Survival (HD) [N = 1503]  | OR 1.10 (0.70–1.70)    | $\hat{\tau}^2 = 34\%$, $p = 0.206$ |
|                      |             | CPC 1–2 (HD) [N = 402]    | OR 1.02 (0.31–3.38)    | $\hat{\tau}^2 = 75\%$, $p = 0.05$ |
|                      |             | Long-term survival (1 year) [N = 1301] | OR 1.38 (0.95–2.02) | $\hat{\tau}^2 = 0.0\%$, $p = 0.647^\text{a}$ |
| Brooks et al. [2] and updated 2014 [3] | 868 and 1166† | Survival (HA) [N = 164] | Not pooled | Studies not pooled |
|                      |             | CPC 1–2 (HD) [N = 767]    | RR 0.41 (0.21–0.79)    | Single study |
|                      |             | Survival (HD) [N = 1063]  | Not pooled | Studies not pooled |
| Gates et al. [4]     | 12,206      | Survival (HA) [N = 7208]  | OR 0.95 (0.85–1.07)    | $\hat{\tau}^2 = 0.0\%$, $p = 0.78$ |
|                      |             | Survival (HD or 30 days) [N = 12,206] | OR 0.89 (0.77–1.02) | $\hat{\tau}^2 = 0.0\%$, $p = 0.49$ |
|                      |             | CPC 1–2 or RS 0–3 (HD) [N = 12,206] | OR 0.76 (0.53–1.11) | $\hat{\tau}^2 = 68\%$, $p = 0.02$ |
| Tang et al. [5]      | 12,510      | Survival (HA) [N = 12,510] | RR 0.94 (0.89–1.00)    | $\hat{\tau}^2 = 0.0\%$, $p = 0.48$ |
|                      |             | Survival (HD) [N = 12,510] | RR 0.88 (0.78–0.99)    | $\hat{\tau}^2 = 27\%$, $p = 0.24$ |
|                      |             | CPC 1–2 or RS 0–3 (HD) [N = 12,058] | RR 0.80 (0.61–1.04) | $\hat{\tau}^2 = 65\%$, $p = 0.04$ |
|                      |             | Long-term survival (2 6 months) [N = 7060] | RR 0.96 (0.79–1.16) | $\hat{\tau}^2 = 16\%$, $p = 0.28$ |
| Li et al. [6]        | 11,162      | Survival (HA), OOH group [N = 9975] | RR 0.97 (0.91–1.04) | $\hat{\tau}^2 = 60\%$, $p = 0.015$ |
|                      |             | Survival (HD), OOH group [N = 4688] | RR 0.99 (0.82–1.18) | $\hat{\tau}^2 = 71\%$, $p = 0.004$ |
|                      |             | Survival (HD), IH group [N = 200] | RR 0.54 (0.29–0.98) | $\hat{\tau}^2 = 0.0\%$, $p = 0.825$ |
|                      |             | CPC 1–2 (HD), OOH group [N = 8885] | RR 1.11 (0.95–1.30) | $\hat{\tau}^2 = 59\%$, $p = 0.032$ |
| Zhan et al. [7]      | 26,742†     | Survival (HA) [N = 520]    | RR 1.18 (0.94–1.48)    | Single study |
|                      |             | Survival (HD) [N = 3031]   | RR 1.21 (1.01–1.46)    | $\hat{\tau}^2 = 0.0\%$, $p = 0.68$ |
|                      |             | CPC 1–2 (HD) [N = 1286]    | RR 1.25 (0.94–1.66)    | Single study |
| **Adrenaline**       |             |                           |                        |              |
| Lin et al. [8]       | 12,246      | Survival (HA) [N = 534]    | RR 1.95 (1.34–2.84)    | Single study |
|                      |             | Survival (HD) [N = 534]    | RR 2.12 (0.75–6.02)    | Single study |
|                      |             | CPC 1–2 (HD) [N = 534]     | RR 1.73 (0.59–5.11)    | Single study |
|                      |             | Survival (HA) [N = 5699]   | RR 0.87 (0.76–1.00)    | $\hat{\tau}^2 = 34\%$, $p = 0.21$ |
|                      |             | Survival (HD) [N = 5638]   | RR 1.04 (0.76–1.42)    | $\hat{\tau}^2 = 0.0\%$, $p = 0.66$ |
|                      |             | CPC 1–2 (HD) [N = 3883]    | RR 1.20 (0.74–1.96)    | $\hat{\tau}^2 = 0.0\%$, $p = 0.33$ |
|                      |             | Survival (HA) [N = 336]    | Not pooled | Single study |
|                      |             | Survival (HD) [N = 336]    | RR 0.68 (0.25–1.82)    | Single study |
|                      |             | CPC 1–2 (HD) [N = 336]     | RR 0.68 (0.25–1.82)    | Single study |
|                      |             | Survival (HA) [N = 4877]   | RR 0.88 (0.73–1.06)    | $\hat{\tau}^2 = 56\%$, $p = 0.06$ |
|                      |             | Survival (HD) [N = 4877]   | RR 1.00 (0.69–1.44)    | $\hat{\tau}^2 = 25\%$, $p = 0.26$ |
|                      |             | CPC 1–2 (HD) [N = 4807]    | RR 1.32 (0.88–1.98)    | $\hat{\tau}^2 = 0.0\%$, $p = 0.85$ |
| Kempton et al. [9]   | 17,635      | Survival (HA) [N = 9511]   | OR 2.52 (1.63–3.88)    | $\hat{\tau}^2 = 84\%$, $p < 0.0001$ |
|                      |             | Survival (HD) [N = 9805]   | OR 1.09 (0.48–2.47)    | $\hat{\tau}^2 = 77\%$, $p = 0.0002$ |
|                      |             | CPC 1–2 or RS 0–3 (HD) [N = 9383] | OR 0.81 (0.34–1.96) | $\hat{\tau}^2 = 83\%$, $p = 0.0005$ |
still have been missed, e.g., 20% relative risk differences in survival cannot be completely excluded for anything that has been tested to-date. This suggests that we need much larger RCTs in this field. Given that CPR is so commonly required, large simple trials should be feasible to do in large enough health care structures. It is important to instill in the future research agenda a strong element of pragmatism, so that the results would be more directly applicable to real-life circumstances. CPR is a good example where “point of care” randomization should be feasible without obtaining consent first given the nature of the intervention. Randomization should be the default option for CPR encounters if a protocol has been approved and set in place. RCTs with sample sizes in the tens of thousands of participants should be the goal.

A challenge in conducting such large-scale pragmatic RCTs is to avoid diluting the potential therapeutic effects by poor choices in the background management of the resuscitated patients. For example, an intervention may be effective by itself, but whatever benefit it produces may be lost if the patients undergo low-quality chest compressions or if they are then sub-optimally managed in the intensive care setting, e.g., improper choices are made for hyperventilation. Meeting both pragmatism and some essential quality standards needs careful design and proper background training of the resuscitating and managing teams.

Another challenge is selecting the proper dose of various interventions to be tested. Several standard choices in the CPR ritual have little evidence to support that the dose, intensity, timing, or frequency used is optimized. For example, the standard dose of adrenaline (1 mg) is largely based on an experiment done over a century ago in 10-kg dogs, in which adrenaline was given at a dose of 0.1 mg/kg. While we have some randomized evidence on higher doses, we have no evidence on lower than standard doses. Timing may also be important. For example, another high-profile recent trial [15] administered epinephrine

| Comparison (setting) | N randomized | Outcome measures (timing) | [N] | Relative risk (95% CI) | Heterogeneity |
|---------------------|-------------|---------------------------|-----|------------------------|--------------|
| Finn et al. [10]    | SDA vs. placebo (OHCA and IHCA) | 21,704 | Survival (HA) [N = 8489] | RR 2.51 (1.67–3.76) | $\hat{\tau} = 77\%, p = 0.04$ |
|                     |             |                           |     | Survival (HD) [N = 8538] | RR 1.44 (1.11–1.86) | $\hat{\tau} = 0.0\%, p = 0.45$ |
|                     |             |                           |     | Neurological outcome (HD) [N = 8535] | RR 1.21 (0.90–1.62) | $\hat{\tau} = 0.0\%, p = 0.49$ |
|                     | SDA vs. HAD (OHCA and IHCA) |  | Survival (HA) [N = 5764] | RR 1.13 (1.03–1.24) | $\hat{\tau} = 0.0\%, p = 0.42$ |
|                     |             |                           |     | Survival (24 h) [N = 4179] | RR 1.04 (0.76–1.43) | $\hat{\tau} = 39\%, p = 0.16$ |
|                     |             |                           |     | Survival (HD) [N = 6274] | RR 1.10 (0.75–1.62) | $\hat{\tau} = 24\%, p = 0.23$ |
|                     |             |                           |     | Neurological outcome (HD) [N = 5803] | RR 0.91 (0.65–1.26) | $\hat{\tau} = 0.0\%, p = 0.42$ |
|                     | SDA vs. vasopressin (OHCA and IHCA) |  | Survival (HA) [N = 1953] | RR 1.27 (1.04–1.54) | $\hat{\tau} = 27\%, p = 0.25$ |
|                     |             |                           |     | Survival (HD) [N = 2511] | RR 1.25 (0.84–1.85) | $\hat{\tau} = 29\%, p = 0.22$ |
|                     |             |                           |     | Neurological outcome (HD) [N = 2406] | RR 0.82 (0.54–1.25) | $\hat{\tau} = 0.0\%, p = 0.46$ |
|                     | SDA vs. SDA + vasopressin (OHCA) |  | Survival (HA) [N = 3249] | RR 0.95 (0.83–1.08) | $\hat{\tau} = 0.0\%, p = 0.55$ |
|                     |             |                           |     | Survival (HD) [N = 3242] | RR 0.76 (0.47–1.22) | $\hat{\tau} = 0.0\%, p = 0.57$ |
|                     |             |                           |     | Neurological outcome (HD) [N = 2887] | RR 0.65 (0.33–1.31) | Single study |
| Vargas et al. [11]  | Epinephrine vs. control (OHCA) | 20,716 | Survival (HA) [N = 20,306] | RR 1.02 (0.75–1.39) | $\hat{\tau} = 96.21\%, p < 0.01$ |
|                     |             |                           |     | Survival (HD) [N = 19,909] | RR 1.16 (1.00–1.35) | $\hat{\tau} = 0.0\%, p = 0.49$ |
|                     |             |                           |     | CPC 1–2 or similar (HD) [N = 18,458]$^e$ | RR 1.24 (1.05–1.48) | $\hat{\tau} = 0.0\%, p = 0.94$ |
| White et al. [12]   | Endotracheal tube intubation vs. supraglottic airway devices (OHCA) | 539,146 | Survival (HA) [N = 51,756] | OR 1.36 (1.12–1.66) | $\hat{\tau} = 91\%, p = 0.002$ |
|                     |             |                           |     | Survival (HD) [N = 440,564] | OR 1.28 (1.02–1.60) | $\hat{\tau} = 96\%, p = 0.03$ |
|                     |             |                           |     | CPC 1–2 or RS < 3 [HD] [N = 438,261] | OR 1.16 (0.94–1.41) | $\hat{\tau} = 91\%, p = 0.16$ |

HA hospital admission, HD hospital discharge, RS Rankin score, OHCA out-of-hospital cardiac arrest, IHCA in-hospital cardiac arrest, SDA standard dose adrenaline, HAD high-dose adrenaline

$^e$Randomized and quasi-randomized studies

$^e$From randomized controlled trials, cluster-randomized controlled trials, and quasi-randomized studies

$^e$CPC 1–2, an overall performance category 1–2, a modified Rankin Scale score 1–2, and a normal or moderate disability
in patients who were largely “dead” (at 20 min post-arrest) and this may have affected its ability to be effective.

Finally, single interventions may have very limited efficacy and effectiveness, but their combination may manage to achieve a breakthrough in success rates. Testing this hypothesis would require running factorial trials, where two randomizations are performed concurrently. Then, one can assess both interventions as well as their joint effect in a statistically efficient manner.

CPR may save lives, and optimizing it should not be left to chance. A rigorous agenda of large pragmatic RCTs is long due. With simple design, the cost of these trials can be minimized, since data collection would pertain to only the most relevant information. Health care systems, insurance, and public agencies could make excellent investments in funding such trials.

Abbreviations
CPR: Cardiopulmonary resuscitation; RCTs: Randomized controlled trials

Acknowledgements
Not applicable.

Authors’ contributions
AC and JPAI wrote and are responsible for the manuscript. Both authors read and approved the final manuscript.

Funding
The Meta-Research Innovation at Stanford (METRICS) is funded by a grant from the Laura and John Arnold Foundation.

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Anesthesiology, University of Thessaly, Larisa, Greece.
2 Hellenic Society of Cardiopulmonary Resuscitation, Athens, Greece.
3 Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, CA 94305, USA.
4 Department of Biomedical Data Science, Stanford University, Stanford, CA 94305, USA.
5 Department of Health Research and Policy, Stanford University, Stanford, CA 94305, USA.
6 Department of Biomedical Data Science, Stanford University, Stanford, CA 94305, USA.
7 Department of Statistics, Stanford University, Stanford, CA 94305, USA.

Received: 1 May 2019 Accepted: 28 May 2019
Published online: 07 June 2019

References
1. Meier P, Baker P, Jost D, Jacobs I, Henzi B, Knapp G, Sasson C. Chest compressions before defibrillation for out-of-hospital cardiac arrest: a meta-analysis of randomized controlled clinical trials. BMJ Med. 2010;8:52.
2. Brooks SC, Bigham BL, Morrison LJ. Mechanical versus manual chest compressions for cardiac arrest. Cochrane Database Syst Rev. 2011;1:CD007260.
3. Brooks SC, Hassan N, Bigham BL, Morrison LJ. Mechanical versus manual chest compressions for cardiac arrest. Cochrane Database Syst Rev. 2014;2:CD007260.
4. Gates S, Quinn T, Deakin CD, Blair L, Couper K, Perkins GD. Mechanical chest compression for out of hospital cardiac arrest: systematic review and meta-analysis. Resuscitation. 2015;84:91–7.
5. Tang L, Gu WJ, Wang F. Mechanical versus manual chest compressions for out-of-hospital cardiac arrest: a meta-analysis of randomized controlled trials. Sci Rep. 2015;5:15635.
6. Li H, Wang D, Yu Y, Zhao X, Jing X. Mechanical versus manual chest compressions for cardiac arrest: a systematic review and meta-analysis. Scand J Trauma Resusc Emerg Med. 2016;24:10.
7. Zhan L, Yang LJ, Huang Y, He Q, Liu GJ. Continuous chest compression versus interrupted chest compression for cardiopulmonary resuscitation of non-asphyxial out-of-hospital cardiac arrest. Cochrane Database Syst Rev. 2017;3:CD010134.
8. Lin S, Callaway CW, Shah PS, Wagner JD, Beyene J, Ziegler CP, Morrison LJ. Adrenaline for out-of-hospital cardiac arrest resuscitation: a systematic review and meta-analysis of randomized controlled trials. Resuscitation. 2014;85(6):32–40.
9. Kempton H, Vlok R, Thang C, Melhuish T, White L. Standard dose epinephrine versus placebo in out of hospital cardiac arrest: a systematic review and meta-analysis. Am J Emerg Med. 2019;37(3):511–7.
10. Finn J, Jacobs I, Williams TA, Gates S, Perkins GD. Adrenaline and vasopressin for cardiac arrest. Cochrane Database Syst Rev. 2019;1:CD003179.
11. Vargas M, Buonanno P, Iacovazzo C, Servillo G. Epinephrine for out of hospital cardiac arrest; a systematic review and meta-analysis of randomized controlled trials. Resuscitation. 2019;136:54–60.
12. White L, Melhuish T, Holyoak R, Ryan T, Kempton H, Vlok R. Advanced airway management in out of hospital cardiac arrest: a systematic review and meta-analysis. Am J Emerg Med. 2018;36(12):2298–306.
13. Newell C, Grier S, Soar J. Airway and ventilation management during cardiopulmonary resuscitation and after successful resuscitation. Crit Care. 2018;22(1):190.
14. Andersen LW, Granfeldt A, Callaway CW, Bradley SM, Soar J, Nolan JP, Kurth T, Donnino MW. Association between tracheal intubation during adult in-hospital cardiac arrest and survival. JAMA. 2017;317(5):494–506.
15. Perkins GD, Ji C, Deakin CD, Quinn T, Nolan JP, Scomparin C, Regan S, Long J, Slowther A, Pocock H, Black JJM, Moore F, Fothergill RT, Rees N, O’Shea L, Docherty M, Gunson I, Han K, Charlton K, Finn J, Petrou S, Stallard N, Gates S, Lall R. PARAMEDIC2 collaborators. A randomized trial of epinephrine in out-of-hospital cardiac arrest. N Engl J Med. 2018;379(8):711–21.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.